Protease Inhibitors and Nephrolithiasis

Last updated April 19, 2015
Case Authors: 
David H. Spach, MD's picture
Real name: 
David H. Spach, MD
Professor of Medicine
Division of Infectious Diseases
Clinical Director, Mountain West AIDS Education and Training Center
University of Washington School of Medicine
Disclosures: 
None
Learning Objectives: 
  1. List protease inhibitors with known risk for causing nephrolithiasis.
  2. Summarize management strategies for patients with protease inhibitor-related nephrolithiasis.

Display Group

References
  1. Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999;58:1165-203.
  2. Reiter WJ, Schön-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol. 1999;161:1082-4.
  3. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-25.
  4. Daudon M, Estépa L, Viard JP, Joly D, Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997;349:1294-5.
  5. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy. N Engl J Med. 1997;336:138-40.
  6. Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF. Protease inhibitor-induced urolithiasis. Urology. 1997;50:508-11.
  7. Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS. 1998;12:F249-54.
  8. Hamada Y, Nishijima T, Watanabe K, et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55:1262-9.
  9. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671-3.
  10. Izzedine H, Lescure FX, Bonnet F. HIV medication-based urolithiasis. Clin Kidney J. 2014;7:121-6.
  11. Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007;45:e105-8.
  12. Kanzaki G, Tsuboi N, Miyazaki Y, Yokoo T, Utsunomiya Y, Hosoya T. Diffuse tubulointerstitial nephritis accompanied by renal crystal formation in an HIV-infected patient undergoing highly active antiretroviral therapy. Intern Med. 2012;51:1543-8.
  13. Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M. Atazanavir nephrotoxicity. Clin Kidney J. 2015;8:137-42.
  14. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One. 2013;8:e77268.
  15. Saltel E, Angel JB, Futter NG, Walsh WG, O'Rourke K, Mahoney JE. Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol. 2000;164:1895-7.
  16. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS. 2007;21:1215-8.
  17. Lafaurie M, De Sousa B, Ponscarme D, et al. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. PLoS One. 2014;9:e112836.
  18. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-8.
  19. Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results. HIV Med. 2002;3:277-82.
  20. Martínez E, Leguizamón M, Mallolas J, Miró JM, Gatell JM. Influence of environmental temperature on incidence of indinavir-related nephrolithiasis. Clin Infect Dis. 1999;29:422-5.
  21. Gagnon RF, Alli AI, Edwardes MD, Watters AK, Tsoukas CM. Low urine pH is associated with reduced indinavir crystalluria in indinavir-treated HIV-infected individuals. Clin Nephrol. 2006;65:13-21.
  22. de Lastours V, Ferrari Rafael De Silva E, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68:1850-6.
  23. Dieleman JP, van Rossum AM, Stricker BC, et al. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr. 2003;32:135-42.